Personnel
Dendreon names Mark Frohlich vice president of clinical affairs
Published in Clinical Oncology Week, April 10th, 2006
Frohlich, a urologic oncologist with over a decade of oncology drug development and patient treatment experience in the public and private sectors, will focus on the completion of the clinical section of the Biologics License Application (BLA) for PROVENGE, which the company is on track to submit to the U.S. Food and Drug Administration (FDA) by the middle of this year and the ongoing Phase 3 IMPACT (D9902B) clinical study of PROVENGE in men with advanced prostate cancer.
Prior to joining Dendreon, Frohlich was vice president and medical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Bladder Cancer
Nonmuscle invasive micropapillary bladder carcinoma treated by early cystectomy - Lung Cancer
Lung cancer treated by irinotecan and cisplatin - Prostate Cancer
Prostate cancer diagnosed after repeat biopsies linked to favorable prognosis - Radiotherapy
Link between quality of life and fatigue in cancer patients receiving radiotherapy assessed - Soft Tissue Sarcomas
Soft tissue sarcoma should not be treated with gemcitabine as first-line chemotherapy - Acute Myeloid Leukemia
Acute myeloid leukemia outcome not improved after daunorubicin, cytarabine, and thioguanine therapy - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
